Showing results (71-80 of 205) with videos related to

Sort By:
Pageof 21
Expert Opinion on Drug Safety|February 24, 2010
Safety profile of new anticancer drugsLaura Mansi, Antoine Thiery-Vuillemin, Thierry Nguyen, et al.
Anticancer Research|April 12, 2012
Extravasation of liposomal doxorubicin induces irritant reaction without vesicant injuryElsa Curtit, Loïc Chaigneau, Julien Pauchot, et al.
Drugs|July 21, 2011
Cabazitaxel: a novel microtubule inhibitorCristian Villanueva, Fernando Bazan, Stefano Kim, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|February 14, 2006
Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancerSamuel Limat, Claire-Hélène Bracco-Nolin, Christine Legat-Fagnoni, et al.
Bulletin Du Cancer|September 13, 2011
[Follow-up in patients with early breast cancer]Tristan Maurina, Loïc Chaigneau, Fernando Bazan, et al.
Targeted Oncology|April 24, 2013
Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06C Villanueva, G Romieu, J Salvat, et al.
Cancer Medicine|August 12, 2014
Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic reviewFrédéric Fiteni, Thierry Nguyen, Dewi Vernerey, et al.
Scientific Reports|December 10, 2023
Influence of pneumatic transportation on the stability of monoclonal antibodiesPierre Coliat, Stéphane Erb, Hélène Diemer, et al.
European Journal of Cancer (Oxford, England : 1990)|August 25, 2019
Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancerXavier Pivot, Mark Pegram, Javier Cortes, et al.
American Journal of Clinical Oncology|April 1, 2008
A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapiesErika Viel, Martin Frederico Demarchi, Loic Chaigneau, et al.
Pageof 21